Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16103946 | 1.00 | L3MBTL1 (0.47) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL17044018 | 0.80 | L3MBTL1 (0.45) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL6888079 | 0.80 | L3MBTL1 (0.45) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL11922772 | 0.79 | PARG (0.44) | DRD2MAPK14 | |
| SCHEMBL16103944 | 0.79 | PARG (0.44) | DRD2MAPK14 | |
| SCHEMBL11905218 | 0.77 | L3MBTL1 (0.44) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL11905220 | 0.77 | L3MBTL1 (0.44) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL11905224 | 0.77 | L3MBTL1 (0.44) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL11905640 | 0.77 | L3MBTL1 (0.44) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL11922373 | 0.76 | PARG (0.36) | L3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | CHRNA5, CHRM5, CHRNA7 | L3MBTL1 4613/4885IP6K1 3231/4885KDM4E 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.